Johannes Mischinger
Overview
Explore the profile of Johannes Mischinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheipner L, Jankovic D, Jasarevic S, Altziebler J, Simunovic I, Mischinger J, et al.
Dtsch Arztebl Int
. 2024 Jun;
121(9):300-301.
PMID: 38934070
No abstract available.
2.
Scheipner L, Baudo A, Jannello L, Siech C, de Angelis M, Tian Z, et al.
World J Urol
. 2024 Apr;
42(1):269.
PMID: 38679642
Objective: The cT1a vs. cT1b substratification was introduced in 1992 but never formally tested since. We tested the discriminative ability of cT1a vs. cT1b substaging on cancer-specific survival (CSS) in...
3.
Scheipner L, Zurl H, Altziebler J, Pichler G, Schopfer-Schwab S, Jasarevic S, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136315
Purpose: To test the association between the Charlson-Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of...
4.
Egger V, Hutterer G, Mischinger J, Seles M, Pichler R, Mannweiler S, et al.
World J Urol
. 2023 Apr;
41(5):1359-1364.
PMID: 37024555
Purpose: Upper tract urothelial carcinoma (UTUC) represents an often aggressive malignancy associated with poor prognosis. Therefore, finding reliable prognostic biomarkers in patients undergoing curative surgery for improved risk stratification is...
5.
Fluhrer H, Hutterer G, Golbeck S, Stidl M, Niedrist T, Pichler R, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221134065.
PMID: 36425872
Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall...
6.
Mischinger J, Schollnast H, Zurl H, Geyer M, Fischereder K, Adelsmayr G, et al.
Front Surg
. 2022 Oct;
9:1013389.
PMID: 36277287
Objective: Guidelines for previous negative biopsy (PNB) cohorts with a suspicion of prostate cancer (PCa) after positive multiparametric (mp) magnetic-resonance-imaging (MRI) often favour the fusion-guided targeted prostate-biopsy (TB) only approach...
7.
Seles M, Mischinger J, Zigeuner R
Eur Urol Open Sci
. 2021 Sep;
32:35-37.
PMID: 34522903
No abstract available.
8.
Barth D, Sareban N, Lindner A, Daller L, Matzhold E, Hutterer G, et al.
Urol Oncol
. 2021 Jul;
39(10):736.e9-736.e16.
PMID: 34247906
Background: The ABO blood group system has been previously discussed as a risk factor to develop, as well as a prognostic factor in non-metastatic renal cell carcinoma (RCC). Controversial findings...
9.
Maas M, Mischinger J, Comperat E, Scharpf M, Fend F, Todenhofer T, et al.
World J Urol
. 2021 Apr;
39(11):4021-4027.
PMID: 33881556
Purpose: The value of bladder cancer (BC) substaging into macroscopic (pT3b) and microscopic (pT3a) perivesical fat extension in lymph node (Ln)-negative patients is controversially discussed and limited evidence for prognostic...
10.
Izquierdo-Luna J, Norz V, Bedke J, Aufderklamm S, Amend B, Mischinger J, et al.
Urology
. 2020 Oct;
147:318.
PMID: 33122055
Objective: Various techniques for orthotopic neobladder (ONB) are currently used and have shown satisfactory oncological and functional outcomes. Among the relevant oncological and functional aspects for long-term follow up is...